Among patients with diabetes receiving PCI, novel antidiabetic agents may reduce risk for acute kidney injury.
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback